GlassScriptPhysician profile
Casimiro Gonzalez
NPI 1851497911
$7,445.60
in general payments reported to CMS, 2019-2025
28 companies · $1,995 in 2025
The $1,995 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $800 · 2020: $632 · 2021: $857 · 2022: $1,307 · 2023: $847 · 2024: $1,008 · 2025: $1,995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,849.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $828.76 | 2021-2025 | Rocklatan, Tryptyr, Eysuvis |
| Bausch & Lomb Americas INC. | $771.72 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| New World Medical,INC. | $737.60 | 2019-2025 | Streamline, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Abbvie INC. | $717.25 | 2022-2025 | |
| Allergan, INC. | $712.27 | 2019-2022 | |
| Oyster Point Pharma, INC. | $564.41 | 2022-2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $493.21 | 2019-2025 | Cequa |
| Mallinckrodt Hospital Products INC. | $448.78 | 2020-2024 | Acthar |
| Novartis Pharmaceuticals Corporation | $306.28 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $256.98 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $200.74 | 2025 | Xdemvy |
| Harrow Eye, LLC | $199.48 | 2025 | Vevye |
| Dompe US, INC. | $189.76 | 2024-2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $185.42 | 2019-2022 | |
| Glaukos Corporation | $140.07 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $119.24 | 2021-2022 | |
| Horizon Therapeutics Plc | $113.99 | 2021-2023 | Tepezza |
| Sight Sciences, INC. | $95.10 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $73.28 | 2019-2021 | |
| Ivantis, INC | $57.45 | 2019-2020 | |
| Biotissue Holdings INC. | $47.91 | 2022 | |
| Shire North American Group INC | $43.10 | 2019 | |
| Mallinckrodt Enterprises LLC | $29.53 | 2019 | |
| Amgen INC. | $29.51 | 2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $28.07 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Galderma Laboratories, L.P. | $18.21 | 2019 | |
| Astellas Pharma US INC | $18.08 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casimiro Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.